NCT06642857 Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric/Gastroesophageal Junction Cancer.
| NCT ID | NCT06642857 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xiangdong Cheng |
| Condition | Advanced Gastric Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 150 participants |
| Start Date | 2024-03-25 |
| Primary Completion | 2026-02-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 150 participants in total. It began in 2024-03-25 with a primary completion date of 2026-02-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this project, based on the information of advanced gastric/gastroesophageal junction cancer in evolution under immunotherapy combined with chemotherapy treatment, we will integrate multi-omics dynamic data to identify essential features that correlate to therapeutic effects of immunotherapy therapy, screen potential molecular markers/dominant microbiota for predicting the efficacy of immunotherapy and establish a multimodal predictive model for patients that benefit from immunotherapy. Our project could provide evidence to predict response to immunotherapy for patients with advanced gastric/gastroesophageal junction cancer and potentially optimize the clinical decision-making about therapy for advanced gastric/gastroesophageal junction cancer.
Eligibility Criteria
Inclusion criteria： * Patients with gastric or gastroesophageal junction adenocarcinoma confirmed by pathology and with advanced or metastatic disease that cannot be resected * HER2 negative * Not received any anti-tumor treatment before. * After evaluation, the treatment plan is chemotherapy combined with immunotherapy. * Aged 18 to 75 years old, gender is not limited. * Expected survival time is greater than or equal to 3 months. Exclusion criteria： * Patients with malignant tumors other than gastric cancer or those with tumors metastasized to the stomach from other sites. * Patients who have previously received anti-tumor treatments such as surgery, radiotherapy and chemotherapy, targeted therapy or immunotherapy. * Patients with severe infections. * Those with a history of mental illness cannot cooperate with the research. * Patients with severe heart, liver, kidney and other diseases. * Pregnant or lactating patients. * HER2 positive.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06642857 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Advanced Gastric Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06642857 currently recruiting?
Yes, NCT06642857 is actively recruiting participants. Contact the research team at Chengxd516@126.com for enrollment information.
Where is the NCT06642857 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06642857 clinical trial?
NCT06642857 is sponsored by Xiangdong Cheng. The trial plans to enroll 150 participants.